Adipocytokines and hepatic fibrosis

Trends Endocrinol Metab. 2015 Mar;26(3):153-61. doi: 10.1016/j.tem.2015.01.002. Epub 2015 Feb 2.

Abstract

Obesity and metabolic syndrome pose significant risk for the progression of many types of chronic illness, including liver disease. Hormones released from adipocytes, adipocytokines, associated with obesity and metabolic syndrome, have been shown to control hepatic inflammation and fibrosis. Hepatic fibrosis is the final common pathway that can result in cirrhosis, and can ultimately require liver transplantation. Initially, two key adipocytokines, leptin and adiponectin, appeared to control many fundamental aspects of the cell and molecular biology related to hepatic fibrosis and its resolution. Leptin appears to act as a profibrogenic molecule, while adiponectin has strong-antifibrotic properties. In this review, we emphasize pertinent data associated with these and other recently discovered adipocytokines that may drive or halt the fibrogenic response in the liver.

Keywords: adipocytokines; adiponectin; hepatic stellate cells; leptin; liver fibrosis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Adipokines / metabolism*
  • Fatty Liver / metabolism*
  • Fatty Liver / pathology
  • Humans
  • Insulin Resistance / physiology*
  • Liver / metabolism*
  • Liver / pathology
  • Liver Cirrhosis / metabolism*
  • Liver Cirrhosis / pathology
  • Metabolic Syndrome / metabolism

Substances

  • Adipokines